Rob Davis, Merck CEO (Credit: The Galien Foundation)
January 8, 2024 08:07 AM ESTUpdated 04:15 PM
Deals

Mer­ck brings Har­poon Ther­a­peu­tics and its PhI/II T cell en­gager in­to the fold for $680M

Amber Tong

Mer­ck has struck a deal to buy Har­poon Ther­a­peu­tics for $680 mil­lion, beef­ing up its on­col­o­gy pipeline with a port­fo­lio of T cell en­gagers. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times